TO STUDY THE EFFECTIVENESS OF RANIBIZUMAB IN THE TREATMENT OF RETINOPATHY OF PREMATURITY

Abstract

The development of retinopathy of prematurity (PH) is directly related to disorders of retinal vascular innervation in premature infants, especially in conditions of hyperoxia after birth. The key mechanism of pathogenesis is the imbalance of angiogenesis, including the phase of vasobliteration and subsequent vasoproliferation. One of the significant advances in PH therapy has been the introduction of VEGF antagonists, including ranibizumab, previously used in the treatment of ophthalmopathy in adults. However, in pediatric ophthalmology, its use still requires additional clinical assessments.